von Hippel-Lindau tumour suppressor
Last updated 8 May 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Audio Version
- Add to preferred sources on Google
The VHL gene provides instructions for making a protein that functions as part of a complex (a group of proteins that work together) called the VCB-CUL2 complex. This complex targets other proteins to be broken down (degraded) by the cell when they are no longer needed. Protein degradation is a normal process that removes damaged or unnecessary proteins and helps maintain the normal functions of cells.
Normal function
The VHL gene provides instructions for making a protein that functions as part of a complex (a group of proteins that work together) called the VCB-CUL2 complex. This complex targets other proteins to be broken down (degraded) by the cell when they are no longer needed. Protein degradation is a normal process that removes damaged or unnecessary proteins and helps maintain the normal functions of cells.
One of the targets of the VCB-CUL2 complex is a protein called hypoxia-inducible factor 2-alpha (HIF-2α). HIF-2α is one part (subunit) of a larger protein complex called HIF, which plays a critical role in the body's ability to adapt to changing oxygen levels. HIF controls several genes involved in cell division, the formation of new blood vessels, and the production of red blood cells. It is the major regulator of a hormone called erythropoietin, which controls red blood cell production. HIF's function is particularly important when oxygen levels are lower than normal (hypoxia). However, when adequate oxygen is available, the VCB-CUL2 complex keeps HIF from building up inappropriately in cells.
The VHL protein likely plays a role in other cellular functions, including the regulation of other genes and control of cell division. Based on this function, the VHL protein is classified as a tumour suppressor, which means it prevents cells from growing and dividing too rapidly or in an uncontrolled way. The VHL protein is also involved in the formation of the extracellular matrix, which is an intricate lattice that forms in the spaces between cells and provides structural support to tissues.
Conditions referring to this gene or chromosome
Other names
pVHL
VHL1
VHL_HUMAN
Related patient information and medicines

Patient information leaflet
Kidney cancer
There are several types of kidney cancer but over 9 out of 10 kidney cancers are "renal cell cancer". This is sometimes called renal adenocarcinoma or ... (A faulty gene which runs in some families may sometimes trigger kidney cancer. Also, people with some rare genetic disorders have a higher risk of developing kidney cancer - for example, von.

Patient information leaflet
Stomach cancer
Most people who develop stomach cancer are over the age of 55. What are the types of stomach cancer. Adenocarcinoma of the stomach In most cases, stomach cancer begins from a cell which is on the inside lining of the stomach (the mucosa). This type of stomach cancer is called adenocarcinoma of the stomach. As the cancer cells multiply: The tumour.

Patient information leaflet
Primary liver cancer
This can be due to the growing cancer itself. It may also be due to ascites - fluid that builds up in the abdomen - which occurs with various liver disorders. What causes primary liver cancer. A cancerous (malignant) tumour starts from one abnormal cell. The exact reason why a cell becomes cancerous is unclear. It is thought that something damages.

Patient information leaflet
Breast cancer
Presence of receptors Some breast cancer cells have receptors, which allow certain types of hormones or proteins to attach to the cancer cell. It affects up to 20% of women with breast cancer and they tend to be a younger age group. See the separate leaflet called Cancer for more general information about cancer. Causes of breast cancer A.

Patient information leaflet
Acromegaly
This causes a range of symptoms that develop gradually, often over several years. The most noticeable symptoms are that your hands and feet become larger and features of your face may become more prominent. The cause is usually a small non-cancerous growth (tumour) in the pituitary gland. Treatment options include surgery to remove the growth and.

Patient information leaflet
Bell's palsy
Bell's palsy is a weakness (paralysis) that causes nerve damage; it affects the nerve fibres that control the muscles of the face. It is due to a problem with the facial nerve. It develops suddenly, usually on one side of the face. The cause is not clear but most cases are probably due to a viral infection. Most people make a full recovery within.
Further reading and references
- von Hippel-Lindau tumour suppressor; MedlinePlus, National Library of Medicine.
- Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011 Oct 15;20(20):3974-85. doi: 10.1093/hmg/ddr324. Epub 2011 Jul 22.
- Kaelin WG Jr. The von hippel-lindau tumor suppressor protein: an update. Methods Enzymol. 2007;435:371-83. doi: 10.1016/S0076-6879(07)35019-2.
- Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145-73. doi: 10.1146/annurev.pathol.2.010506.092049.
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004 Dec 15;22(24):4991-5004. doi: 10.1200/JCO.2004.05.061.
- Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J, Vasselli JR, Ried T, Zbar B, Choyke P, Walther MM, Klausner RD, Linehan WM. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat. 2004 Jan;23(1):40-6. doi: 10.1002/humu.10302.
- McMullin MF. HIF pathway mutations and erythrocytosis. Expert Rev Hematol. 2010 Feb;3(1):93-101. doi: 10.1586/ehm.09.68.
- Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C; Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9;346(19):1459-66. doi: 10.1056/NEJMoa020152.
- Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, Prchal JF, Prchal JT. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet. 2003 Aug;73(2):412-9. doi: 10.1086/377108. Epub 2003 Jul 3.
- Percy MJ, Rumi E. Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. Am J Hematol. 2009 Jan;84(1):46-54. doi: 10.1002/ajh.21313.
- Percy MJ. Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology. 2007 Apr;12(2):131-9. doi: 10.1080/10245330601111979.
- Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol. 2004 Jul;287(1):F1-6. doi: 10.1152/ajprenal.00424.2003.
Join the conversation
Share your thoughts or experiences with others in our patient communities.

Ask, share, connect.
Browse discussions, ask questions, and share experiences across hundreds of health topics.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.